Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Oncogene

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8302603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger.

  1993cited by this paper
• A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor

  1993cited by this paper
• Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene.

  1993cited by this paper
• The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor.

  1992cited by this paper
• Requirements for phosphorylation of MAP kinase during meiosis in Xenopus oocytes.

  1992cited by this paper
• Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

  1992cited by this paper
• Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains.

  1992cited by this paper
• Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene.

  1991cited by this paper
• Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase.

  1991cited by this paper
• The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase.

  1991cited by this paper
• SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.

  1991cited by this paper
• c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase.

  1991cited by this paper
• Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

  1991cited by this paper
• Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

  1991cited by this paper
• Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

  1991cited by this paper
• Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.

  1991cited by this paper
• The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation

  1991cited by this paper
• Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors.

  1990cited by this paper
• A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes.

  1990cited by this paper
• Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein.

  1990cited by this paper
• Src homology region 2 domains direct protein-protein interactions in signal transduction.

  1990cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Biosynthesis of the protein encoded by the c-met proto-oncogene.

  1989cited by this paper
• Tyrosine kinase receptor indistinguishable from the c-met protein

  1989cited by this paper
• The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

  1988cited by this paper
• Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases.

  1988cited by this paper
• Relationship of site-specific beta subunit tyrosine autophosphorylation to insulin activation of the insulin receptor (tyrosine) protein kinase activity.

  1988cited by this paper
• Identification of the insulin receptor tyrosine residues undergoing insulin-stimulated phosphorylation in intact rat hepatoma cells.

  1988cited by this paper
• A thousand and one protein kinases.

  1987cited by this paper
• Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

  1987cited by this paper
• A tail of two src's: mutatis mutandis.

  1987cited by this paper
• Identification of insulin receptor tyrosine residues autophosphorylated in vitro.

  1987cited by this paper
• Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose.

  1986cited by this paper
• Autophosphorylation of the insulin receptor in vitro. Designation of phosphorylation sites and correlation with receptor kinase activation.

  1986cited by this paper
• Protein-tyrosine kinases.

  1985cited by this paper
• Molecular cloning of a new transforming gene from a chemically transformed human cell line

  1984cited by this paper
• Amino acid alterations within a highly conserved region of the Rous sarcoma virus src gene product pp60src inactivate tyrosine protein kinase activity

  1984cited by this paper
• "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

  1981cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Isolation of phosphorylated peptides and proteins on ion exchange papers.

  1978cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• MET Activation in Lung Cancer and Response to Targeted Therapies

  2025cites this paper
• Deletion of the plexin-D1 ectodomain leads to anoikis by suppressing integrin inside-out signaling.

  2025cites this paper
• MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies

  2025cites this paper
• Tyrosine-Mediated Static and Dynamic Quenching of a Receptor Tyrosine Kinase Biosensor Reveals Inhibitor Binding Modes and Kinase Conformations.

  2025cites this paper
• MET receptor tyrosine kinase promotes the generation of functional synapses in adult cortical circuits

  2024cites this paper
• Recording and classifying MET receptor mutations in cancers

  2024cites this paper
• PHA-665752’s Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells

  2024cites this paper
• Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer.

  2024cites this paper
• Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain

  2024cites this paper
• An Observatory for the MET Oncogene: A Guide for Targeted Therapies

  2023cites this paper
• Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics

  2023cites this paper
• The Receptor Tyrosine Kinase c-Met Promotes Lipid Accumulation in 3T3-L1 Adipocytes

  2023cites this paper
• Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding

  2023cites this paper
• Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain

  2023cites this paper
• IQGAP1 Is a Phosphotyrosine-Regulated Scaffold for SH2-Containing Proteins

  2023influential citation
• Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

  2022cites this paper
• Functional analysis of MET exon 14 skipping alteration in cancer invasion and metastatic dissemination.

  2022cites this paper
• c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance

  2022cites this paper
• When the MET receptor kicks in to resist targeted therapies

  2021cites this paper
• A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET.

  2021cites this paper
• The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives

  2020cites this paper
• Spectrum of Mesenchymal–Epithelial Transition Aberrations and Potential Clinical Implications: Insights From Integrative Pancancer Analysis

  2020cites this paper
• Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization

  2020cites this paper
• Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB.

  2020cites this paper
• MET receptor in oncology: From biomarker to therapeutic target.

  2020cites this paper
• Novel Peptide CM 7 Targeted c-Met with Antitumor Activity

  2020cites this paper
• Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase

  2019cites this paper
• Met Receptor Activation

  2019cites this paper
• Phosphatase of regenerating liver sensitizes MET to functional activation by hepatocyte growth factor.

  2019cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation

  2018cites this paper
• C-MET inhibitors for advanced non-small cell lung cancer

  2018cites this paper
• The multiple paths towards MET receptor addiction in cancer

  2018cites this paper
• [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].

  2018cites this paper
• Translational studies on acute myeloid leukemia focus on the receptor tyrosine kinase FLT3

  2018cites this paper
• Balance of Forces: Regulation of protein tyrosine phosphorylation by PTPs and RTKs in glioma

  2018cites this paper
• Activated HGF-c-Met Axis in Head and Neck Cancer

  2017cites this paper
• MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

  2017cites this paper
• Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD

  2017influential citation
• High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form.

  2016cites this paper
• Regulation of the MET oncogene: molecular mechanisms.

  2016cites this paper
• Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.

  2016cites this paper
• Combined systemic elimination of MET and epidermal growth factor receptor signaling completely abolishes liver regeneration and leads to liver decompensation

  2016influential citation
• D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts

  2016cites this paper
• Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

  2016cites this paper
• The use of combination tyrosine kinase inhibitors for the treatment of glioblastoma multiforme

  2016cites this paper
• The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer

  2016cites this paper
• Distinct intracellular signaling mediates C‐MET regulation of dendritic growth and synaptogenesis

  2016cites this paper
• The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation.

  2016cites this paper
• Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

  2015cites this paper
• Identification of Tyrosine-Phosphorylated Proteins Upregulated during Epithelial-Mesenchymal Transition Induced with TGF-β.

  2015cites this paper
• Development of antibody-based c-Met inhibitors for targeted cancer therapy

  2015cites this paper
• Diffuse gliomas: exploiting molecular and metabolic characteristics for improved diagnosis and therapy

  2015cites this paper
• Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects

  2015cites this paper
• Ablation of Dicer leads to widespread perturbation of signaling pathways.

  2015influential citation
• Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab.

  2015cites this paper
• TGF-β Negatively Regulates CXCL1 Chemokine Expression in Mammary Fibroblasts through Enhancement of Smad2/3 and Suppression of HGF/c-Met Signaling Mechanisms

  2015cites this paper
• Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

  2015cites this paper
• Complementary PTM Profiling of Drug Response in Human Gastric Carcinoma by Immunoaffinity and IMAC Methods with Total Proteome Analysis

  2015cites this paper
• Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

  2014cites this paper
• Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

  2014cites this paper
• Resistance to targeted cancer drugs through hepatocyte growth factor signaling

  2014cites this paper
• Effets des clivages du récepteur tyrosine kinase Met par les calpaïnes sur la motilité et la mort cellulaire

  2014cites this paper
• SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene.

  2014cites this paper
• Physiological Signaling and Structure of the HGF Receptor MET

  2014cites this paper
• ROLE OF CXCL1 SIGNALING IN STROMA: EPITHELIUM INTERACTIONS DURING BREAST CANCER PROGRESSION

  2014cites this paper
• Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice

  2014cites this paper
• Role of Met Axis in Head and Neck Cancer

  2013cites this paper
• Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

  2013cites this paper
• Mutationsanalyse und Charakterisierung von transkriptionellen Targetgenen des Metastasierungs-induzierenden Gens MACC1

  2013influential citation
• Cancer Therapy : Preclinical Tivantinib ( ARQ 197 ) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

  2013cites this paper
• Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

  2013cites this paper
• The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer

  2013cites this paper
• Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis

  2013cites this paper
• Anti‐c‐MET Nanobody® – a new potential drug in multiple myeloma treatment

  2013cites this paper
• 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.

  2013cites this paper
• The role of CD44v6 in RTK internalization and trafficking

  2013cites this paper
• A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene

  2013cites this paper
• 3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells.

  2013cites this paper
• Shedding‐Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway

  2012cites this paper
• Hepatocyte growth factor/c-Met signalling is important for the selection of transplanted hepatocytes

  2012cites this paper
• Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed.

  2012cites this paper
• Molecular pathology of lung cancer: key to personalized medicine

  2012cites this paper
• Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

  2012cites this paper
• Met degradation: more than one stone to shoot a receptor down

  2012cites this paper
• Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.

  2012cites this paper
• A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

  2012cites this paper
• Correction: A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

  2012cites this paper
• Anti-tumor effect of β-elemene in murine hepatocellular carcinoma cell line H22 depends on the level of c-Met downregulation

  2012cites this paper
• Effect of globin digest on the liver injury and hepatic gene expression profile in galactosamine-induced liver injury in SD rats.

  2011cites this paper
• The autism risk genes MET and PLAUR differentially impact cortical development

  2011cites this paper
• Signaling Pathways in the Liver

  2011cites this paper
• The role of the c-Met pathway in lung cancer and the potential for targeted therapy

  2011cites this paper
• Structural insights into Met receptor activation.

  2011cites this paper
• WNT AND BETA-CATENIN IN HEPATIC DIFFERENTIATION: WHICH WAY DOES THE WNT BLOW?

  2011cites this paper
• Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway

  2011cites this paper
• Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

  2011cites this paper
• Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function*

  2011cites this paper